BioMarin Appoints Two BioPharmaceutical Veterans to Board of Directors, Willard Dere, M.D. and Kathryn E. Falberg
18 July 2016 - 10:31PM
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in
providing therapies for rare genetic diseases, today announced the
appointment of two biopharmaceutical veterans to its Board of
Directors: Willard Dere, M.D., Professor of Internal Medicine at
the University of Utah Health Sciences Center and former Senior
Vice President in Research and Development at Amgen and Kathryn E.
Falberg, former Chief Financial Officer of Jazz Pharmaceuticals and
Amgen.
“We are thrilled to have Dr. Dere and Ms. Falberg both join
BioMarin’s Board of Directors. They represent some of the
most talented leaders in the biopharmaceutical industry and bring
additional industry experience in drug development and finance to
an already outstanding board,” said Jean-Jacques Bienaimé, Chairman
and Chief Executive Officer at BioMarin. “I am confident they
will make meaningful contributions to support BioMarin through a
transformative period of growth, as we continue to develop
therapies to meet the unmet medical needs of patients with rare
genetic diseases.”
“I am honored to serve on the board of a company that shares my
passion for translating exciting science into important therapies
to address unmet medical needs,” said Willard Dere, M.D. “I look
forward to working with BioMarin to help further its efforts to
deliver first-in-class and best-in-class therapies to treat
patients with rare genetic diseases.”
“I admire BioMarin as a pioneer in developing therapies for rare
disease patients and am delighted to become a member of the board,”
said Kathryn E. Falberg. “It is an exciting time to join the
company, as it continues to build its current business, while
advancing its robust pipeline during a time of exceptional
growth.”
Dr. Dere and Ms. Falberg join Jean-Jacques Bienaimé, Chairman
and Chief Executive Officer, Lead Independent Director Richard
Meier, International Executive Vice President and Chief Financial
Officer, Owens & Minor, Inc., Michael Grey, President and Chief
Executive Officer, Amplyx Pharmaceuticals, Inc., Elaine J. Heron,
Ph.D., Director and former Chief Executive Officer, Amplyx
Pharmaceuticals, Inc, V. Bryan Lawlis, President and Chief
Executive Officer, Itero Biopharmaceuticals, LLC, Alan Lewis,
Ph.D., Chief Executive Officer, DiaVacs, Inc., David Pyott, former
Chief Executive Officer of Allergan plc. and Dennis J. Slamon,
M.D., Ph.D., Professor of Medicine, UCLA Department of Medicine as
BioMarin’s Board of Directors.
About Willard Dere, M.D.
Dr. Willard Dere is Professor of Internal Medicine; B. Lue and
Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine
for Diabetes Research, Executive Director of Personalized Health,
and Co-Principal Investigator of the Center for Clinical and
Translational Science at the University of Utah Health Sciences
Center. Prior to re-joining academia in November 2014, Dr.
Dere was in the biopharmaceutical industry for 25 years. He
joined Amgen in 2003 where he held multiple roles including head of
global development, international research and development, and
both corporate and international chief medical officer. He
led the development programs for Prolia and several other programs,
and retired from Amgen in October 2014. He began his career
at Eli Lilly in 1989, and held a number of different global roles
in clinical pharmacology, regulatory affairs, and both early-stage
translational, and late-stage clinical research. While at Eli
Lilly, he led the development of Evista and Forteo. Since
2014, he has been a member of the Board of Directors for Radius
Health and serves on the scientific advisory board of the
California Institute of Regenerative Medicine.
Dr. Dere attended undergraduate and medical school at the
University of California, Davis. He trained in internal medicine at
the University of Utah and endocrinology/ metabolism at the
University of California at San Francisco, and was on the Internal
Medicine faculty at the University of Utah for 4 years during which
time he was recognized annually with teaching awards. He has
published numerous articles; wrote and co-edited a primary care
textbook; was awarded the 2008 transformational leadership award
from his alma mater; and is a fellow in the American College of
Physicians.
About Kathryn E. Falberg
Ms. Kathryn E. Falberg served as Executive Vice President and
Chief Financial Officer of Jazz Pharmaceuticals plc, a
multi-national specialty biopharmaceutical company, from March 2012
to March 2014 after serving as Senior Vice President and Chief
Financial Officer since December 2009. Her responsibilities
at Jazz Pharmaceuticals included strategy, corporate development,
corporate communications and information technology. During
this period, the company grew rapidly and completed a number of
significant acquisitions and financing transactions. From
2001 through 2009, Ms. Falberg worked with a number of smaller
companies while serving as a corporate director and audit committee
chair for several companies. From 1995 to 2001, Ms. Falberg
was with Amgen, a leading global biotechnology company, where she
served as Senior Vice President, Finance and Strategy and Chief
Financial Officer and prior to that as Vice President Chief
Accounting Officer, and Vice President, Treasurer. Ms.
Falberg received an M.B.A. and B.A., in Economics from the
University of California, Los Angeles and is a certified public
accountant, inactive.
Ms. Falberg also serves as a member of the board of directors
for biopharmaceutical companies Medivation, Aimmune Therapeutics,
and aTyr Pharma. Ms. Falberg previously served on the board
of directors of Halozyme Therapeutics, QLT, Human Genome Sciences,
VISX, and Fresh del Monte.
About BioMarin
BioMarin is a global biotechnology company that develops and
commercializes innovative therapies for people with serious and
life-threatening rare disorders. The company's portfolio consists
of five commercialized products and multiple clinical and
pre-clinical product candidates.
For additional information, please visit www.BMRN.com.
Information on BioMarin's website is not incorporated by reference
into this press release.
BioMarin® is a registered trademarks of BioMarin Pharmaceutical
Inc.
Contacts:
Investors
Traci McCarty
BioMarin Pharmaceutical Inc.
(415) 455-7558
Media
Debra Charlesworth
BioMarin Pharmaceutical Inc.
(415) 455-7451
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Apr 2024 to May 2024
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From May 2023 to May 2024